Table 4.
Patient | Control | ||||
---|---|---|---|---|---|
OPG G209A | n=19 | % | n=21 | % | p value |
GG | |||||
GA | 3 | 15.8 | 1 | 4.8 | >0.05 |
AA | 16 | 84.2 | 20 | 95.2 | >0.05 |
polymorphism were termed GG, GA, and AA; G indicates the presence of the restriction site at −209
| |||||
OPG T245G | n=20 | % | n=20 | % | p value |
TT | |||||
TG | 3 | 15.0 | 0 | 0 | >0.05 |
GG | 17 | 85.0 | 20 | 100 | >0.05 |
polymorphism were termed TT, TG, and GG; T indicates the presence of the restriction site at −245
| |||||
IL-6 G-174C | n=20 | % | n=17 | % | p value |
GG | |||||
GC | 10 | 50.0 | 7 | 41.2 | >0.05 |
CC | 10 | 50.0 | 10 | 58.8 | >0.05 |
polymorphism were termed GG, GC, and CC; G indicates the presence of the restriction site at −174 |